249.29 USD
↘ 10.90 (4.19%)AT CLOSE (11:59 AM EDT)
Jazz Pharmaceuticals, Inc.
JAZZNASDAQ • USD
249.61
↗ 0.32 (0.13%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
249.61
↗ 0.32 (0.13%)
Market: CLOSED
JAZZ is currently priced at $249.44. The stock presents a mixed profile: our models indicate a Buy for underlying fundamentals, while technical indicators flash a Sell. This is driven by a bullish Golden Cross on the moving averages. On valuation, JAZZ trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of Aug 26, 2026.
Open?$257.40
High?$259.83
Low?$248.52
Prev. Close?$260.23
Volume?2.4M
Avg. Volume?744.6K
VWAP?$254.39
Rel. Volume?3.25x
Bid / Ask
Bid?$235.98 × 100
Ask?$265.21 × 100
Spread?$29.23
Midpoint?$250.59
Valuation & Ratios
Market Cap?16.9B
Shares Out?64.9M
Float?62.2M
Float %?95.8%
P/E Ratio?17.96
P/B Ratio?3.52
EPS?$14.49
Dividend?0.00%
Ex-Dividend?N/A
RelatedAXSM
News
Profile
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Themes
Employees
2.9K
Market Cap
16.9B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2007-06-01
Address
FIFTH FLOOR, WATERLOO EXCHANGE
DUBLIN, D04 E5W7
Phone: 353-1-634-7800
DUBLIN, D04 E5W7
Phone: 353-1-634-7800
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?77
Z-Score?57
Momentum?69
Short Sent.?64
Piotroski F-Score?6/9Mixed
Altman Z-Score?2.59Grey
Confidence?81%High
Short InterestElevated
Short % of Float?5.81%Elevated
Short Interest?3.6M
Days to Cover?3.8
Free Float62.2M
Avg Daily Volume949.5K
Settlement Date2026-08-14
Financial Health
Current Ratio?1.78Adequate
Quick Ratio?1.58Adequate
Cash Ratio?0.73Adequate
Debt/Equity?0.91Moderate
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score78/100
P/E?18.0CHEAP▾
S&P72
P/B?3.52FAIR▾
Peers100
S&P49
P/S?3.67FAIR▾
Peers100
S&P42
P/FCF?11.2CHEAP▾
S&P85
EV/EBITDA?12.2FAIR▾
S&P67
EV/Sales?4.27FAIR▾
Peers100
S&P43
Returns & Efficiency
ROE?19.6%STRONG▾
S&P65
ROA?8.5%STRONG▾
S&P68
Cash Flow & Enterprise
FCF?$1.5B
Enterprise Value?$19.6B
Fundamentals ratios updated end of day